Citation Impact
Citing Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
2009
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
2008
Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis: a systematic review.
2012
Building Predictive Models in R Using the caret Package
2008 Standout
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
2017
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
2010
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
2012 Standout
Bias in random forest variable importance measures: Illustrations, sources and a solution
2007 Standout
Conditional variable importance for random forests
2008 Standout
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
2011
Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems
2011
The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation
2020 Standout
A comparative study of discriminating human heart failure etiology using gene expression profiles
2005
The clinician’s guide to prevention and treatment of osteoporosis
2022
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records
2016 Standout
An extensive comparison of recent classification tools applied to microarray data
2004
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary
2016
Osteoporosis
2019 Standout
Quantification of mRNA using real-time RT-PCR
2006 Standout
Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics
2009
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Cellular mechanisms of bone remodeling
2010
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
mixOmics: An R package for ‘omics feature selection and multiple data integration
2017 Standout
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
2012
ilastik: interactive machine learning for (bio)image analysis
2019 Standout
Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis
2013
The role of inflammation in diabetic eye disease
2019
An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging, and random forests.
2009 Standout
Osteoporosis: now and the future
2011 Standout
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
2010
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019
Microbial Co-occurrence Relationships in the Human Microbiome
2012 Standout
Machine Learning methods for Quantitative Radiomic Biomarkers
2015 Standout
Treatment of osteoporosis with denosumab
2010
Partial least squares: a versatile tool for the analysis of high-dimensional genomic data
2006
A comparison of random forest variable selection methods for classification prediction modeling
2019 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment
2012
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials
2016
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Novel patterns of response under immunotherapy
2019
Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data
2005
Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab
2013
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Idiopathic pulmonary fibrosis
2017 Standout
Age-related macular degeneration
2018 Standout
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
SoilGrids250m: Global gridded soil information based on machine learning
2017 Standout
Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy
2017 Standout
Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry
2015
A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models
2019 Standout
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis
2011
Management of severe osteoporosis
2015
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
2009
Clinical targeting of the TNF and TNFR superfamilies
2013
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Skeletal and extraskeletal actions of denosumab
2012
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
2017
Gene selection and classification of microarray data using random forest
2006 Standout
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
2012
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Denosumab and bisphosphonates: Different mechanisms of action and effects
2010
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Hepatocellular carcinoma
2022 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Differing effects of denosumab and alendronate on cortical and trabecular bone
2013
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
2016
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
2016
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect
2010
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Feature Selection with theBorutaPackage
2010 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
2012 Standout
MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data
2018 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Emerging drugs for postmenopausal osteoporosis
2009
Evaluating Microarray-based Classifiers: An Overview
2008
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
2018
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
2018 Standout
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
2011
Machine learning methods for solar radiation forecasting: A review
2017 Standout
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
2012
The amazing osteocyte
2010 Standout
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
2016
Graph-based approach for airborne light detection and ranging segmentation
2017 Standout
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
A review of feature selection techniques in bioinformatics
2007 Standout
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
2016
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
Works of Beiying Ding being referenced
Development of atrophy in neovascular AMD treated with ranibizumab in the HARBOR study
2015
Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program
2017
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
2012
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
2017
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy–Neutropenia (FACT-N)
2007
Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
2010
Effects of Denosumab on the Geometry of the Proximal Femur in Postmenopausal Women in Comparison with Alendronate
2008
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
2008
Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
2007
Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE
2016
Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
2007
Classification Using Generalized Partial Least Squares
2005
Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)
2020
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer
2018
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
2010
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
2018
Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
2011